VYNE Therapeutics Inc. (NASDAQ:VYNE) Sees Large Decline in Short Interest

VYNE Therapeutics Inc. (NASDAQ:VYNE) was the target of a significant decline in short interest in January. As of January 30th, there was short interest totaling 544,777 shares, a decline of 27.6% from the January 15th total of 752,574 shares. Based on an average daily volume of 520,008 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.7% of the shares of the company are short sold. Approximately 1.7% of the shares of the company are short sold. Based on an average daily volume of 520,008 shares, the days-to-cover ratio is currently 1.0 days.

Wall Street Analysts Forecast Growth

Several research firms have commented on VYNE. Wall Street Zen raised shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 2nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of VYNE Therapeutics in a report on Wednesday, January 21st. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, VYNE Therapeutics has an average rating of “Reduce” and an average price target of $4.50.

Institutional Investors Weigh In On VYNE Therapeutics

Institutional investors have recently bought and sold shares of the business. Patient Square Capital LP lifted its holdings in VYNE Therapeutics by 23.3% in the 2nd quarter. Patient Square Capital LP now owns 317,033 shares of the company’s stock worth $523,000 after purchasing an additional 60,000 shares during the last quarter. Kennedy Capital Management LLC bought a new position in shares of VYNE Therapeutics during the second quarter valued at $942,000. Velan Capital Investment Management LP acquired a new position in VYNE Therapeutics in the second quarter valued at about $50,000. TFG Asset Management GP Ltd acquired a new position in shares of VYNE Therapeutics in the 2nd quarter worth approximately $190,000. Finally, Jane Street Group LLC bought a new stake in shares of VYNE Therapeutics during the second quarter worth $206,000. 83.78% of the stock is currently owned by institutional investors and hedge funds.

VYNE Therapeutics Price Performance

Shares of VYNE opened at $0.57 on Friday. The firm’s 50 day moving average is $0.54 and its 200-day moving average is $0.42. VYNE Therapeutics has a 12-month low of $0.28 and a 12-month high of $2.94. The stock has a market capitalization of $18.98 million, a P/E ratio of -0.73 and a beta of 2.02.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.